Lasofoxifene

Lasofoxifene
Clinical data
Trade names	Fablyn
Routes of; administration	By mouth
Drug class	Selective estrogen receptor modulator
ATC code	G03XC03 (WHO) ;
Identifiers
	IUPAC name (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;
CAS Number	180916-16-9 ;
PubChem CID	216416;
IUPHAR/BPS	7542;
ChemSpider	187585 ;
UNII	337G83N988;
ChEBI	CHEBI:135938;
ChEMBL	ChEMBL328190 ;
CompTox Dashboard (EPA)	DTXSID50171037 ;
Chemical and physical data
Formula	C28H31NO2
Molar mass	413.55 g/mol; 563.64 g/mol (tartrate) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(cc1)[C@@H]4c2ccc(O)cc2CC[C@@H]4c3ccccc3)CCN5CCCC5;
	InChI InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1 ; Key:GXESHMAMLJKROZ-IAPPQJPRSA-N ;
	(what is this?) (verify)

Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.